Resources Repository
-
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Test Performance | Cost-Effectiveness Analysis | Decision Analysis | Costing Methods | Health Outcomes | Global | Chronic Disease/Risk | Probability/Bayes | Preferences/Values | Value of Information | State-Transition | Infectious Diseases | Child/Nutrition | Economics/Finance | Health/Medicine | North America | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Evidence Synthesis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Benefit-Cost Analysis | Health Outcomes | Global | Chronic Disease/Risk | Priority Setting/Ethics | Microsimulation | Health Systems -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Technology Assessment | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Priority Setting/Ethics | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Costing Methods | Health Outcomes | Global | Chronic Disease/Risk | Evidence Synthesis | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | State-Transition | Microsimulation | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Priority Setting/Ethics | Infectious Diseases | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ArticlePublication 2016Essential Package of Cancer Control: Costs, Affordability, and Feasibility of an Essential Package of Cancer Control Interventions in LMIC Countries
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in …
Investments in cancer control-prevention, detection, diagnosis, surgery, palliative care-are needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Disease Control Priorities, 3rd edition developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of…
Cost-Effectiveness Analysis | Costing Methods | Global | Chronic Disease/Risk | Health Systems | Health/Medicine | Science/Technology -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Priority Setting/Ethics | Infectious Diseases | Mental Health | Health Systems | Economics/Finance | Health/Medicine